Evidence map›Paper›PMID 32805281›Full record

ArticleGastroenterology2020

The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling.

Baoqing Chen, Mihnea P Dragomir, Linda Fabris, Recep Bayraktar, Erik Knutsen, Xu Liu, Changyan Tang, Yongfeng Li, Tadanobu Shimura, Tina Catela Ivkovic and 38 more

Open access · greenAbstract read
In one paragraph

Article in Gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. AURKB drives aggressive phenotype and clinicopathological progression in cholangiocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

48 authors at 13 institutions in 8 countries.

Baoqing ChenDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Mihnea P DragomirDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of General Surgery, Fundeni Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Linda FabrisDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Recep BayraktarDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Erik KnutsenDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Medical Biology, Faculty of Health Sciences, The Arctic University of Norway, Tromsø, Norway.
Xu LiuDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Changyan TangDepartment of Chemistry, University of Washington, Seattle, Washington.
Yongfeng LiDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Tadanobu ShimuraCenter for Gastrointestinal Research; Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute, Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas.
Tina Catela IvkovicCentral European Institute of Technology, Masaryk University, Brno, Czech Republic.
Mireia Cruz De Los SantosDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Simone AnfossiDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Masayoshi ShimizuDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Maitri Y ShahDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hui LingDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Peng ShenDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Asha S MultaniDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Barbara PardiniDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jared K BurksDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hiroyuki KatayamaDepartment of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.
Lucas C ReinekeDepartment of Neuroscience, Baylor College of Medicine, Houston, Texas.
Longfei HuoDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Muddassir SyedDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Shumei SongDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Manuela FerracinDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Eiji OkiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Bastian FrommScience for Life Laboratory, Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Cristina IvanDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Krithika BhuvaneshwarInnovation Center for Biomedical Informatics, Georgetown University, Washington, District of Columbia.
Yuriy GusevInnovation Center for Biomedical Informatics, Georgetown University, Washington, District of Columbia.
Koshi MimoriDepartment of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
David MenterDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Subrata SenDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Takatoshi MatsuyamaDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan.
Hiroyuki UetakeDepartment of Specialized Surgeries, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Catalin VasilescuDepartment of General Surgery, Fundeni Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Scott KopetzDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jan Parker-ThornburgDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ayumu TaguchiDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Samir M HanashDepartment of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.
Leonard GirnitaDepartment of Oncology-Pathology, Bioclinicum, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.
Ondrej SlabyCentral European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Ajay GoelCenter for Gastrointestinal Research; Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute, Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas.
Gabriele VaraniDepartment of Chemistry, University of Washington, Seattle, Washington.
Mihai GageaDepartment of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Chunlai LiDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: CLi10@mdanderson.org.
Jaffer A AjaniDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: jajani@mdanderson.org.
George A CalinDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: gcalin@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USBaylor University Medical Center · USCentral European Institute of Technology · CZGeorgetown University · USTokyo Medical and Dental University · JPUniversity of Bologna · ITUniversity of Washington · USBaylor College of Medicine · USCarol Davila University of Medicine and Pharmacy · ROKarolinska University Hospital · SEKyushu University · JPKyushu University Beppu Hospital · JPOslo University Hospital · NO

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI Louis M Weiner · 1990 to 2026
$71.5M
UPR/MDACC Partnership for Excellence in Cancer Research(Parent Grant U54 CA096297)U54CA096297 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI SHARON Hermes GIORDANO, REYNOLD Eugenio LOPEZ-ENRIQUEZ · 2002 to 2026
$36.9M
UPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHARON Hermes GIORDANO · 2002 to 2026
$23.8M
The Biology and Diagnosis of HNPCCR01CA072851 · NCI · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI GOEL, AJAY · 1996 to 2019
$6.6M
ncRNA: Structure, Interactions and InhibitionR35GM126942 · NIGMS · UNIVERSITY OF WASHINGTON · PI Gabriele Varani · 2018 to 2026
$6.0M
Novel extra cellular RNA-based combinatorial RNA inhibition therapyUH3TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2015 to 2017
$3.2M
Protein-coding and non-coding RNA biomarkers for early detection of CLLR01CA182905 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABRUZZO, LYNNE V., CALIN, GEORGE A. · 2014 to 2018
$2.9M
miR-155 targeted therapeutics for precision medicine in lung cancerR01CA222007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., CRISTINI, VITTORIO · 2018 to 2022
$2.6M
MicroRNA Biomarkers for Determining Treatment Response in Colorectal CancerR01CA202797 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GOEL, AJAY · 2016 to 2020
$1.9M
High-resolution modeling of protein-RNA interfacesR01GM121487 · NIGMS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2017 to 2020
$1.7M
METHYLATION BIOMARKER DEVELOPMENT FOR NONINVASIVE DETECTION OF COLORECTAL CANCERR01CA181572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GOEL, AJAY · 2014 to 2018
$1.6M
NCATS NIH HHS UH3 TR000943NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA072851NCI NIH HHS R01 CA181572NCI NIH HHS R01 CA182905NCI NIH HHS R01 CA202797NCI NIH HHS R01 CA222007NCI NIH HHS R50 CA211121NCI NIH HHS R50 CA243707NCI NIH HHS U54 CA096297NCI NIH HHS U54 CA096300NIGMS NIH HHS R01 GM121487NIGMS NIH HHS R01 GM122775NIGMS NIH HHS R35 GM126942
6 · The paper itself

Abstract

BACKGROUND &

aimsChromosomal instability (CIN) is a carcinogenesis event that promotes metastasis and resistance to therapy by unclear mechanisms. Expression of the colon cancer-associated transcript 2 gene (CCAT2), which encodes a long noncoding RNA (lncRNA), associates with CIN, but little is known about how CCAT2 lncRNA regulates this cancer enabling characteristic.

methodsWe performed cytogenetic analysis of colorectal cancer (CRC) cell lines (HCT116, KM12C/SM, and HT29) overexpressing CCAT2 and colon organoids from C57BL/6N mice with the CCAT2 transgene and without (controls). CRC cells were also analyzed by immunofluorescence microscopy, γ-H2AX, and senescence assays. CCAT2 transgene and control mice were given azoxymethane and dextran sulfate sodium to induce colon tumors. We performed gene expression array and mass spectrometry to detect downstream targets of CCAT2 lncRNA. We characterized interactions between CCAT2 with downstream proteins using MS2 pull-down, RNA immunoprecipitation, and selective 2'-hydroxyl acylation analyzed by primer extension analyses. Downstream proteins were overexpressed in CRC cells and analyzed for CIN. Gene expression levels were measured in CRC and non-tumor tissues from 5 cohorts, comprising more than 900 patients.

resultsHigh expression of CCAT2 induced CIN in CRC cell lines and increased resistance to 5-fluorouracil and oxaliplatin. Mice that expressed the CCAT2 transgene developed chromosome abnormalities, and colon organoids derived from crypt cells of these mice had a higher percentage of chromosome abnormalities compared with organoids from control mice. The transgenic mice given azoxymethane and dextran sulfate sodium developed more and larger colon polyps than control mice given these agents. Microarray analysis and mass spectrometry indicated that expression of CCAT2 increased expression of genes involved in ribosome biogenesis and protein synthesis. CCAT2 lncRNA interacted directly with and stabilized BOP1 ribosomal biogenesis factor (BOP1). CCAT2 also increased expression of MYC, which activated expression of BOP1. Overexpression of BOP1 in CRC cell lines resulted in chromosomal missegregation errors, and increased colony formation, and invasiveness, whereas BOP1 knockdown reduced viability. BOP1 promoted CIN by increasing the active form of aurora kinase B, which regulates chromosomal segregation. BOP1 was overexpressed in polyp tissues from CCAT2 transgenic mice compared with healthy tissue. CCAT2 lncRNA and BOP1 mRNA or protein were all increased in microsatellite stable tumors (characterized by CIN), but not in tumors with microsatellite instability compared with nontumor tissues. Increased levels of CCAT2 lncRNA and BOP1 mRNA correlated with each other and with shorter survival times of patients.

conclusionsWe found that overexpression of CCAT2 in colon cells promotes CIN and carcinogenesis by stabilizing and inducing expression of BOP1 an activator of aurora kinase B. Strategies to target this pathway might be developed for treatment of patients with microsatellite stable colorectal tumors.

Indexed as

Chromosomal InstabilityAnimalsAntineoplastic Combined Chemotherapy ProtocolsAurora Kinase BAzoxymethaneCarcinogenesisCell Line, TumorColonColorectal NeoplasmsCytogenetic AnalysisDextransDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansAURKB protein, humanAurora Kinase BAzoxymethaneBOP1 protein, humanDextranslong non-coding RNA CCAT2, humanMYC protein, humanProto-Oncogene Proteins c-mycRNA-Binding ProteinsRNA, Long NoncodingAneuploidyMSSNoncoding RNATumorigenesis

Identifiers

PMID32805281
PMCPMC7725986
OpenAlexW3049148296

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.